E Fund Management’s Vanda Pharmaceuticals VNDA Stock Holding History

E Fund Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,603	Closed	-$80.2K	–	519
2026 Q1	$80.2K	Buy	+11,603	New	+$89.5K	﹤0.01%	478
2023 Q3	–	Sell	-11,832	Closed	-$78K	–	322
2023 Q2	$78K	Sell	11,832 -1,228	-9%	-$7.87K	0.01%	304
2023 Q1	$89K	Buy	+13,060	New	+$91.8K	0.01%	324

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

E Fund Management's VNDA Position: Q2 2026 in Review

E Fund Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 11,603 shares — an estimated $80.2K sold.

E Fund Management first reported a position in VNDA in Q1 2023 and held it in 3 quarters. The position peaked at $89K in Q1 2023. 173 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

E Fund Management reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
E Fund Management sold 11,603 Vanda Pharmaceuticals shares in Q2 2026, an estimated $80.2K.
E Fund Management first reported a position in Vanda Pharmaceuticals in Q1 2023 and held it in 3 quarters.
E Fund Management's Vanda Pharmaceuticals position peaked at $89K in Q1 2023.
173 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.